Cyberonics NCP Depression Indication May Be Tonic For Medtronic Blues
This article was originally published in The Gray Sheet
Executive Summary
Cyberonics will create a separate 214-member depression sales and marketing team for the NCP NeuroCybernetic Prosthesis vagus nerve stimulation system and have it in place by the beginning of 2002, or roughly six months before the company expects FDA approval for the indication, CEO Skip Cummins reported at a Sept. 21 teleconference.
You may also be interested in...
Cyberonics Faces Challenge Of Expectations In Wake Of Failed Medtronic Bid
Cyberonics likely will face increased pressure to execute its long term business plan and meet rising shareholder expectations now that Medtronic's unwelcome $480 mil. acquisition proposal has been withdrawn.
Cyberonics Faces Challenge Of Expectations In Wake Of Failed Medtronic Bid
Cyberonics likely will face increased pressure to execute its long term business plan and meet rising shareholder expectations now that Medtronic's unwelcome $480 mil. acquisition proposal has been withdrawn.
Medtronic Holding Pat On $480 Mil. Acquisition Offer Spurned By Cyberonics
Medtronic's stalled $480 mil. acquisition bid for Cyberonics may be the first test for President and Chief Operating Officer Arthur Collins as he prepares to assume the top executive post at Medtronic next spring.